AKT1 and breast carcinoma: We observed that treatment with the PI3K inhibitor LY294002 resulted in a significant reduction of breast cancer cell migration in response to BMCM (Fig 6C; P≤0.05), whereas treatment with the Akt inhibitor Triciribine or a vehicle control had no effect (Fig 6C).